Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Deferred royalty obligation

Deferred royalty obligation at other companies

Ardelyx logo
ArdelyxARDX
$6.5M+1.4%
Ardelyx logo
ArdelyxARDX
$6.5M+1.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$879.37M+8.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$879.37M+8.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$21.79M+1,071%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$29.28M

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$944.15M-1.3%
Enterprise value$798.74M-3.1%
P/E19.7×-6.7×
P/S1.2×-0.2×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept coll:DeferredRoyaltyLiabilityNonCurrent.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemJune 30,2026December 31,2025
Term notes payable, net of current portion797,824542,112
Convertible senior notes238,733238,213
Operating lease liabilities, net of current portion3,4074,132
Deferred royalty obligation121,357121,563
Deferred revenue, net of current portion8,7789,111
Contingent consideration, net of current portion22,956
Deferred tax liabilities40,965
Total liabilities1,823,8811,355,159

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s deferred royalty obligation?
Collegium Pharmaceutical, Inc. (COLL) reported deferred royalty obligation of $121.36M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s deferred royalty obligation changed year-over-year?
Collegium Pharmaceutical, Inc.'s deferred royalty obligation decreased by 1.0% year-over-year, from $122.63M to $121.36M.
What does deferred royalty obligation mean?
This represents the long-term portion of obligations to pay royalties to third parties, typically arising from licensing agreements or the acquisition of intellectual property rights. It reflects future cash commitments tied to the commercial success or sales of specific products. Tracking this liability is important for understanding long-term margin pressure and the cost structure associated with licensed technologies.

Ask your AI about Collegium Pharmaceutical, Inc.'s deferred royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude